Chromadex Corp (OTCMKTS:CDXC) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Friday.

Several other analysts have also commented on CDXC. Zacks Investment Research lowered Chromadex Corp from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 15th. HC Wainwright set a $5.00 price target on Chromadex Corp and gave the stock a “buy” rating in a research note on Friday, August 11th.

Shares of Chromadex Corp (OTCMKTS CDXC) traded up 3.06% on Friday, hitting $4.04. The company had a trading volume of 730,693 shares. The stock’s 50-day moving average is $3.33 and its 200 day moving average is $3.16. Chromadex Corp has a 52 week low of $2.25 and a 52 week high of $4.19. The company’s market capitalization is $186.22 million.

Chromadex Corp (OTCMKTS:CDXC) last posted its earnings results on Thursday, August 10th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of $0.04 by $0.09. The company had revenue of $5.31 million for the quarter, compared to analyst estimates of $11 million. Chromadex Corp had a negative return on equity of 63.19% and a negative net margin of 52.09%. Equities analysts expect that Chromadex Corp will post ($0.14) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “ValuEngine Upgrades Chromadex Corp (CDXC) to “Hold”” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/09/valuengine-upgrades-chromadex-corp-cdxc-to-hold.html.

In related news, major shareholder Step Holdings Ltd Pioneer acquired 786,167 shares of Chromadex Corp stock in a transaction that occurred on Friday, August 18th. The shares were purchased at an average price of $2.60 per share, for a total transaction of $2,044,034.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Robert N. Fried acquired 10,000 shares of Chromadex Corp stock in a transaction that occurred on Tuesday, August 15th. The shares were bought at an average price of $3.15 per share, for a total transaction of $31,500.00. Following the transaction, the insider now owns 583,241 shares of the company’s stock, valued at approximately $1,837,209.15. The disclosure for this purchase can be found here. Insiders bought 798,167 shares of company stock worth $2,082,154 over the last ninety days.

A number of large investors have recently bought and sold shares of CDXC. Segall Bryant & Hamill LLC raised its holdings in shares of Chromadex Corp by 0.3% in the 1st quarter. Segall Bryant & Hamill LLC now owns 38,834 shares of the company’s stock valued at $104,000 after buying an additional 133 shares during the period. Bank of Montreal Can purchased a new stake in shares of Chromadex Corp in the 2nd quarter valued at $168,000. LMR Partners LLP purchased a new stake in shares of Chromadex Corp in the 2nd quarter valued at $347,000. Goldman Sachs Group Inc. raised its holdings in shares of Chromadex Corp by 870.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock valued at $698,000 after buying an additional 163,817 shares during the period. Finally, North Star Investment Management Corp. raised its holdings in shares of Chromadex Corp by 78.9% in the 2nd quarter. North Star Investment Management Corp. now owns 265,334 shares of the company’s stock valued at $1,014,000 after buying an additional 117,000 shares during the period.

About Chromadex Corp

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Chromadex Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex Corp and related companies with MarketBeat.com's FREE daily email newsletter.